Literature DB >> 33390969

Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis.

Nan Ding1, Bo Wei2, Xiaohui Fu1, Chuan Wang1, Yimou Wu1.   

Abstract

Fibrosis is a common pathway followed by different organs after injury, and it can lead to parenchymal scarring, cellular dysfunction, and even organ failure. The NLRP3 inflammasome is a multiprotein complex composed of the sensor molecule NLRP3, the adaptor apoptosis-associated speck-like protein containing a CARD (ASC), and the effector protease caspase-1. Overactivation of the NLRP3 inflammasome triggers the abundant secretion of IL-1β and IL-18, induces pyroptosis, and promotes the release of a swathe of proinflammatory proteins, all of which contribute to fibrogenic processes in multiple organs. In recent years, screening bioactive natural compounds for NLRP3 inhibitors to alleviate fibrosis has gained broad interest from the scientific community because of the associated cost-effectiveness and easy access. In this review, we systematically and comprehensively summarize the natural products, including terpenoids, phenols, and alkaloids, among others, and the plant-derived crude extracts, that have been reported to ameliorate fibrosis via inhibiting NLRP3 inflammasome activation and highlight the underlying mechanisms. Among all the compounds, diterpenoids is the most promising candidates for inhibiting NLRP3 inflammasome activation and improving fibrosis, as they possess combined inhibitory effect on NLRP3 inflammasome assembly and NF-κB signaling pathway. All the information may aid in the development of therapeutic strategies for the treatment of fibrotic diseases.
Copyright © 2020 Ding, Wei, Fu, Wang and Wu.

Entities:  

Keywords:  NLRP3 inflammasome; fibrosis; herbs; phenols; phytochemicals; terpenoids

Year:  2020        PMID: 33390969      PMCID: PMC7773645          DOI: 10.3389/fphar.2020.591393

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  6 in total

Review 1.  Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases.

Authors:  Fang Hua; Lingli Shi; Peng Zhou
Journal:  Inflammopharmacology       Date:  2022-01-17       Impact factor: 4.473

2.  Inhibitory effect of low‑intensity pulsed ultrasound on the fibrosis of the infrapatellar fat pad through the regulation of HIF‑1α in a carrageenan‑induced knee osteoarthritis rat model.

Authors:  Takashi Kitagawa; Hirohisa Kawahata; Motokuni Aoki; Shintarou Kudo
Journal:  Biomed Rep       Date:  2022-08-09

Review 3.  The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis.

Authors:  Carol M Artlett
Journal:  Biomolecules       Date:  2022-04-26

Review 4.  Inflammasome as an Effective Platform for Fibrosis Therapy.

Authors:  Ting-Ting Chen; Feng Xiao; Nan Li; Shan Shan; Meng Qi; Zi-Ying Wang; Sheng-Nan Zhang; Wei Wei; Wu-Yi Sun
Journal:  J Inflamm Res       Date:  2021-04-20

5.  Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial.

Authors:  Adel A Gomaa; Hamdy S Mohamed; Rasha B Abd-Ellatief; Mohamed A Gomaa; Doaa S Hammam
Journal:  Inflammopharmacology       Date:  2022-03-01       Impact factor: 4.473

Review 6.  A Selective Review and Virtual Screening Analysis of Natural Product Inhibitors of the NLRP3 Inflammasome.

Authors:  Sherihan El-Sayed; Sally Freeman; Richard A Bryce
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.